Physician profile
Jay B Patel
NPI 1316104839
$5,134.34
in general payments reported to CMS, 2019-2025
20 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,389 · 2020: $30.14 · 2021: $164 · 2022: $581 · 2023: $561 · 2024: $268 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,959.36 | 2019 | |
| Abiomed | $490.66 | 2022-2024 | Impella |
| Atricure, INC. | $411.70 | 2022-2024 | |
| Zimmer Biomet Holdings, INC. | $386.62 | 2019-2021 | |
| Medtronic, INC. | $162.64 | 2023-2025 | Corevalve Evolut R, Penditure |
| Baxter Healthcare | $128.57 | 2022 | |
| Abbott Laboratories | $118.73 | 2020-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Intuitive Surgical, INC. | $74.78 | 2021 | |
| Getinge USA Sales, LLC | $61.40 | 2023-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Ethicon US, LLC | $57.63 | 2022 | |
| Haemonetics Corporation | $49.27 | 2025 | Teg6s Hemostasis System |
| Angiodynamics, INC. | $39.12 | 2023-2024 | Angiovac |
| Werfen USA LLC | $32.20 | 2021 | |
| Lemaitre Vascular, INC. | $32.10 | 2024 | Artegraft Vascular Graft |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.15 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.15 | 2019-2020 | |
| Artivion, INC. | $21.88 | 2019 | |
| Nuwellis, INC. | $19.62 | 2019 | |
| Solventum Corporation | $18.05 | 2024 | V.A.C. Veraflo |
| Amgen INC. | $17.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.